Aragen Expands Collaboration With MSD To Provide Discovery Services To Support MSD's Global R&D

Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), headquartered out of Hyderabad, India, announced the expansion of its collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) to provide discovery services and solutions supporting MSD’s global R&D efforts.

“We look forward to continuing to work with MSD researchers to advance its pipeline of therapeutic candidates,” said Manni Kantipudi, CEO of Aragen. “At Aragen, our team believes that ‘in every molecule is the possibility for better health’. By treating every project with urgency and focus, we look to discover and develop medicines for our collaborators that make a positive impact on patients.”

Dr. Sudhir Kumar Singh, COO of Aragen, added: “On behalf of all Aragenites, I want to thank MSD for their trust and confidence in us and their decision to expand on the collaboration. Over the past several years, we have worked diligently at building a world-class scientific team, equipping them with state-of-the-art infrastructure, and inculcating a culture of customer-centricity.”